Avalo Therapeutics (STU:C6K0) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:C6K0 Avalo Therapeutics Inc STU:C6K0
44 GF Score
Price €15.76
GF Value €0.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Avalo Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

STU:C6K0 vs SANA, ANRO, REPL: Short Percentage of Float Comparison

For the Biotechnology subindustry, Avalo Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Avalo Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avalo Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Avalo Therapeutics's Short Percentage of Float falls into.


STU:C6K0
44GF Score
Avalo Therapeutics Inc STU:C6K0
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Avalo Therapeutics (STU:C6K0) Overvalued in 2026?

Based on GuruFocus' analysis, Avalo Therapeutics stock appears to be overvalued. The current stock price of €15.76 is trading 52433.3% above its estimated GF Value™ of €0.03. GuruFocus considers Avalo Therapeutics to be Significantly Overvalued.

Key valuation signals for STU:C6K0:

  • Short Percentage of Float:
  • GF Value™: €0.03 vs. price of €15.76 (52433.3% above fair value)
  • GF Score™: 44/100 with 5 warning signs

No single metric tells the full story. See the STU:C6K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Avalo Therapeutics Business Description

Other Exchanges AVTX:USA
Address 1500 Liberty Ridge Drive, Suite 321, Wayne, PA, USA, 19087
Avalo Therapeutics Inc is a clinical stage biotechnology company fully dedicated to developing IL-1B-based treatments for immune-mediated inflammatory diseases. The company's asset is Abdakibart (AVTX-009) an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalos pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein), AVTX-006 and AVTX-913.
44GF Score

Get the complete analysis for STU:C6K0

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€15.76
Price
€0.03
GF Value